Clinical Studies

Perimetric Comparison Between the IMOvifa™ and Humphrey® Field Analyzer (HFA™)

AUTHORS:

Nishida T, Eslani M, Weinreb RN, Arias J, Vasile C, Mohammadzadeh V, Moghimi S. Vasile C, Mohammadzadeh V, Moghimi S.

PUBLICATION:

J Glaucoma. 2023 Feb 1;32(2):85-92. Epub 2022 Oct 7.

Robert N Weinreb: Commercial Relationship(s): Code C (Consultant/Contractor), Code F (Financial Support): Topcon Corporation. Remaining authors declare no conflict of interest.32(2): 85-92. Epub 2022 Oct 7.

Study Purpose

To evaluate the performance of IMOvifa, a perimeter that performs binocular visual field (VF) testing, and to compare its results with standard automated perimetry.

Overview

Study Design

Observational,
cross-sectional study

138 eyes of
69 patients

including healthy, glaucoma suspects, and primary open angle glaucoma

Study Device

IMO Smart Visual Function Analyzer (referred to as IMOvifa SVFA)*
Humphrey® Field Analyzer (HFATM)
Melbourne Rapid Fields (MRF)

*IMOvifa is known as TEMPO in the USA

Outcome Measures

Primary: Mean deviation (MD), pattern standard deviation (PSD), foveal threshold, visual field index (VFI)

Secondary: Measurement time for visual field

Results

IMOvifa reduced measurement time by 39%
No significant difference in MD (-3.1 dB for HFA vs. -3.1 dB for IMOvifa, P>0.05) or VFI (93.1% for HFA vs. 92.6% for IMOvifa; P>0.05) between HFA 24-2 SITA-Fast and IMOvifa 24-2 AIZE-Rapid
Significant differences were seen in mean PSD (3.2 dB for HFA vs. 4.1 dB for IMOvifa, P<0.001) and foveal threshold (33.9 dB for HFA vs. 30.6 dB for IMOvifa, P<0.001)
Correlation was strong for MD (r=0.90, P<0.001), PSD (r=0.78, P<0.001), and VFI (r=0.94, P<0.001)
The mean difference (95% limits of agreement) was -0.1 (-3.8, 3.5) dB for MD, -0.4 (-3.4, 2.5) dB for PSD, and 0.1 (-8.9, 9.1) dB for VFI, respectively (Figure 1)
Diagnostic accuracies differentiating glaucomatous and healthy eyes were similar for MD and PSD (P>0.05 for both), but not for VFI (P=0.031), from pairwise comparisons of AUROC (Figure 2)

IMOvifa reduced measurement time by

39%

FIGURE 1.

Bland-Altman diagram with median difference and agreement limits (including 95% of all difference values). Adapted from J Glaucoma. 2023 Feb 1; 32(2): 85-92. Epub 2022 Oct 7.

FIGURE 2

FIGURE 2.

Area under the receiver operator characteristic curves for mean deviation (A), pattern SD (B), and visual field index (C). Adapted from J Glaucoma. 2023 Feb 1;32(2):85-92. Epub 2022 Oct 7.

Conclusions

IMOvifa AIZE-Rapid showed good agreement and strong deviation, and visual field index. Additionally, IMOvifa shortened visual field test time for healthy and glaucoma patients and reduced fatigue for both patients and examiners.